Free tool
FAERS Monitor: Briviact
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205838 or its brand name (Briviact, Brivaracetam). Reports on generic versions are filed under their own applications.
Reports
9,327
Serious
7,450
80% of reports
Hospitalization
2,552
Death reported
467
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- seizure3,353
- off label use1,195
- drug ineffective1,051
- fatigue600
- therapy interrupted545
- somnolence532
- overdose516
- dizziness479
- product availability issue403
- fall381
- generalised tonic-clonic seizure360
- epilepsy352
- product dose omission issue349
- product use issue320
- headache315
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 5 |
| 2016 | 107 |
| 2017 | 231 |
| 2018 | 435 |
| 2019 | 773 |
| 2020 | 692 |
| 2021 | 931 |
| 2022 | 1,034 |
| 2023 | 1,205 |
| 2024 | 1,261 |
| 2025 | 1,396 |
| 2026 | 1,253 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,832 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| seizureSignal | 3,353 | 67.4 | 65.5 | 214,043 |
| generalised tonic-clonic seizureSignal | 360 | 50.1 | 45.2 | 16,921 |
| product availability issueSignal | 403 | 40.6 | 36.9 | 15,274 |
| epilepsySignal | 352 | 26.3 | 23.7 | 8,440 |
| therapy interruptedSignal | 545 | 17.3 | 16.0 | 8,330 |
| somnolenceSignal | 532 | 6.0 | 5.5 | 2,212 |
| overdoseSignal | 516 | 5.4 | 5.0 | 1,863 |
| product use issueSignal | 320 | 3.8 | 3.5 | 676 |
| off label useSignal | 1,195 | 3.1 | 2.9 | 1,747 |
| product dose omission issueSignal | 349 | 2.7 | 2.4 | 370 |
| fallSignal | 381 | 2.6 | 2.3 | 374 |
| dizzinessSignal | 479 | 2.2 | 2.0 | 307 |
| drug ineffective | 1,051 | 1.8 | 1.7 | 397 |
| fatigue | 600 | 1.7 | 1.6 | 195 |
| headache | 315 | 1.1 | 1.0 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.